1. Combined Analysis of Molecular and Clinical Predictors of Gefitinib Activity in Advanced Non–Small Cell Lung Cancer: Epidermal Growth Factor Receptor Mutations Do Not Tell the Whole Story 
Athanassios Argiris, MD, Thomas Hensing, MD, Anjana Yeldandi, MD, Smita Patel, MD, Adekunle Raji, BS, Charles Sturgis, MD, Gregory Masters, MD, William Gooding, MSc, Michael Pins, MD, Jill Kolesar, PharmD 
Journal of Thoracic Oncology 
Volume 1, Issue 1, Pages (January 2006)
DOI: /S (15)
Copyright © 2006 International Association for the Study of Lung Cancer Terms and Conditions

2. FIGURE 1
Kaplan-Meier survival curve of overall survival according to the development of rash after gefitinib therapy.
Journal of Thoracic Oncology 2006 1, 52-60DOI: ( /S (15) )
Copyright © 2006 International Association for the Study of Lung Cancer Terms and Conditions

3. FIGURE 2
Kaplan-Meier survival curve of time to progression with gefitinib therapy according to AKT protein expression in the tumor. AKT positivity by immunohistochemistry was associated with a trend toward longer time to progression (p=0.08).
Journal of Thoracic Oncology 2006 1, 52-60DOI: ( /S (15) )
Copyright © 2006 International Association for the Study of Lung Cancer Terms and Conditions